Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 391
Filter
1.
Article in English | WPRIM | ID: wpr-880372

ABSTRACT

INTRODUCTION@#The survival of HIV/AIDS patients on antiretroviral therapy (ART) is determined by a number of factors, including economic, demographic, behavioral, and institutional factors. Understanding the survival time and its trend is crucial to developing policies that will result in changes. The aim of this study was to compare the survival estimates of different subgroups and look into the predictors of HIV/AIDS patient survival.@*METHODS@#A retrospective cohort study of HIV/AIDS patients receiving ART at the University of Gondar teaching hospital was carried out. To compare the survival of various groups, a Kaplan-Meier survival analysis was performed. The Cox proportional hazards model was used to identify factors influencing HIV/AIDS patient survival rates.@*RESULTS@#In the current study, 5.91% of the 354 HIV/AIDS patients under ART follow-up were uncensored or died. Age (HR = 1.051) and lack of formal education (HR = 5.032) were associated with lower survival rate, whereas family size of one to two (HR = 0.167), three to four (HR = 0.120), no alcoholic consumption (HR = 0.294), no smoking and chat use (HR = 0.101), baseline weight (HR = 0.920), current weight (HR = 0.928), baseline CD4 cell count (HR = 0.990), baseline hemoglobin (HR = 0.800), and no TB diseases were associated with longer survival rate.@*CONCLUSIONS@#Fewer deaths were reported in a study area due to high patient adherence, compared to previous similar studies. Age, educational status, family size, alcohol consumption, tobacco and chat usage, baseline and current weight, baseline CD4 cell count, baseline hemoglobin, and tuberculosis (TB) diseases were all significant predictors of survival of HIV/AIDS patients.


Subject(s)
Adolescent , Adult , Aged , Aged, 80 and over , Anti-HIV Agents/therapeutic use , Cohort Studies , Ethiopia/epidemiology , Female , HIV Infections/mortality , Hospitals , Humans , Male , Middle Aged , Proportional Hazards Models , Retrospective Studies , Survival Rate , Young Adult
2.
Cad. Saúde Pública (Online) ; 37(9): e00143520, 2021. tab, graf
Article in English | LILACS | ID: biblio-1345635

ABSTRACT

Immune recovery reflects health conditions. Our goal was to estimate the time it takes to achieve immune recovery and its associated factors, in people living with HIV (PLHIV), after antiretroviral therapy (ART) initiation. A historical cohort study was performed among PLHIV (> 18 years-old) in Minas Gerais State, Brazil, using data from healthcare databases. Patients initiating ART between 2009-2018, with T-CD4+ lymphocytes and viral load recorded before and after antiretroviral therapy were included. The outcome is achievement of immune recovery, defined as the first T-CD4+ > 500 cells/µL after ART initiation. Explanatory variables were age, gender, place of residence, year of ART initiation, baseline viral load and T-CD4+, viral load status, and adherence to ART at follow-up. Descriptive analysis, cumulative, and person-time incidences of immune recovery were estimated. Median-time to immune recovery was estimated using Kaplan-Meier method. Factors associated with immune recovery were assessed by Cox regression. Among 26,430 PLHIV, 8,014 (30%) were eligible. Most were male (67%), mean age 38.7 years, resided in non-central region, median-baseline T-CD4+ = 228 cells/µL (< 200 cells/µL = 43%) and viral load median-baseline = 4.7 log10 copies/mL (detectable viral load = 99%). Follow-up time = 15,872 person-years. Cumulative and incidence rate were 58% (95%CI: 57-58) (n = 4,678) and 29.47 cases/100 person-years, respectively. Median-time to immune recovery was of 22.8 months (95%CI: 21.9-24.0). Women living with HIV, younger than 38 years of age, with T-CD4+ baseline > 200 cells/µL, detectable viral load (baseline), antiretroviral therapy-adherence and undetectable viral load (follow-up) were independently associated with immune recovery. Time to immune recovery remains long and depends on early treatment and antiretroviral therapy-adherence.


A recuperação imunológica reflete condições de saúde. Nosso objetivo foi estimar o tempo até a recuperação imunológica e fatores associados em pessoas vivendo com HIV (PVHIV) após de iniciar a terapia antirretroviral (TARV). Foi conduzida uma coorte histórica de PVHIV (> 18 anos) no Estado de Minas Gerais, Brasil, usando bancos de serviços públicos de saúde. Foram incluídos pacientes que iniciaram a TARV entre 2009 e 2018, com linfócitos T-CD4+ e carga viral registrados antes e depois do início da TARV. O desfecho foi a recuperação imunológica, definida como a primeira contagem de T-CD4+ > 500 cel/µL após o início da TARV. As variáveis explanatórias foram idade, sexo, local de residência, ano de início de TARV, carga viral basal, T-CD4+ na linha de base e carga viral e adesão à TARV no seguimento. Foi realizada uma análise descritiva com estimativa de incidência acumulada e taxa de incidência (pessoa-ano). O tempo mediano até a recuperação imunológica foi estimado pelo método Kaplan-Meier. Fatores associados à recuperação imune foram avaliados por meio de regressão de Cox. Entre as 26.430 PVHIV, 8.014 (30%) foram elegíveis. A maioria era do sexo masculino (67%), com média de idade = 38,7 anos, residência em regiões fora da região metropolitana, mediana de T-CD4+ baseline = 228 células/µL (< 200 células/µL = 43%) e mediana de carga viral baseline = 4,7 log10 cópias/mL (carga viral detectável = 99%). Tempo de seguimento = 15.872 pessoas-ano. A incidência acumulativa e a taxa de incidência foram foram 58% (IC95%: 57-58) (n = 4.678) e 29,47 casos/100 pessoas-ano, respectivamente. Tempo mediano até recuperação imune = 22,8 meses (IC95%: 21,9-24,0). Os fatores independentemente associados com recuperação imunológica foram sexo feminino, idade < 38 anos, T-CD4+ basal > 200 células/µL, carga viral detectável (linha de base), adesão à TARV e carga viral indetectável (no seguimento). O tempo até a recuperação imunológica ainda é longo e impactado pelo tratamento precoce e da adesão à TARV.


La recuperación inmunológica refleja condiciones de salud. Nuestra meta fue estimar el tiempo y los factores asociados a la recuperación inmunológica en personas que viven con VIH (PVVIH), tras iniciar una terapia antirretroviral (TAR). Se realizó sobre una cohorte histórica entre PVVIH (> 18 años de edad) en Minas Gerais, Brasil, usando datos de las bases de datos del sistema de salud. Se incluyeron a pacientes que comenzaron una TAR entre 2009-2018, con T-CD4+ linfocitos y carga viral, registrada antes/después de TAR. El resultado fue el logro de recuperación inmunológica, definida como la primera T-CD4+ > 500 células/µL tras la iniciación TAR. Las variables explicatorias fueron: edad, género, lugar de residencia, año de iniciación TAR, base de referencia de carga viral, base de referencia de T-CD4+ y estatus de la carga viral y adherencia al TAR en el seguimiento. Se estimó: análisis descriptivo, acumulativo e incidencias persona-tiempo de recuperación inmunológica. La media de tiempo para la recuperación inmunológica se estimó usando el método Kaplan-Meier. Los factores asociados con la recuperación inmunológica se evaluaron mediante la regresión de Cox. Entre las 26.430 PVVIH, 8.014 (30%) fueron elegibles. La mayoría eran hombres (67%), media de edad = 38,7 años, residentes en una región no central, media de base de referencia T-CD4+ = 228 células/µL (< 200 células/µL = 43%) y carga viral media de base de referencia = 4,7 log10 copias/mL (carga viral detectable = 99%). El tiempo de seguimiento = 15.872 persona-años. La tasa acumulativa y de incidencia fue 58% (95%CI: 57-58) (n = 4.678) y 29,47 casos/100 persona-años, respectivamente. El tiempo de media para la recuperación inmunológica = 22,8 meses (95%CI: 21,9-24,0). Género femenino, PVVIH < 38 años de edad, T-CD4+ base de referencia > 200 células/µL, carga viral detectable (base de referencia), adherencia al TAR e carga viral indetectable (seguimiento) estuvieron independientemente asociadas con la recuperación inmunológica. El tiempo para la recuperación inmunológica sigue siendo largo y depende de un tratamiento temprano y de adherencia a la TAR.


Subject(s)
Humans , Male , Female , Adolescent , Adult , HIV Infections/drug therapy , Anti-HIV Agents/therapeutic use , Brazil , Cohort Studies , Viral Load , Antiretroviral Therapy, Highly Active
3.
Rev. chil. infectol ; 37(5): 550-554, nov. 2020. tab, graf
Article in Spanish | LILACS | ID: biblio-1144249

ABSTRACT

Resumen Introducción: Cargas virales (CV) entre 20-200 copias/mL se consideran cargas virales de bajo grado (CVBG). Su implicancia clínica y manejo no han sido definidos. Objetivo: Evaluar el impacto de CVBG en el riesgo de desarrollo posterior de fallo virológico (FV). Pacientes y Métodos: Se incluyeron pacientes ≥ 18 años, desde enero de 2009 a diciembre de 2019, con infección por VIH-1 con CV< 20 copias/mL, por un mínimo de seis meses y/o en dos muestras consecutivas bajo tratamiento anti-retroviral . Se realizó seguimiento de las CV estrati ficándolas: CV < 20 copias/mL, CVBG (20-50 copias/mL y 51-200 copias/mL) y FV. Mediana de seguimiento 25 meses (IQR 15-31). Resultados: Fueron incluidos 1.416 pacientes con CV < 20 copias/ mL bajo TARV. De ellos, 797 permanecieron con CV< 20 copias/mL durante el seguimiento, 144 presentaron CV entre 20-50 copias/mL, 384 entre 51-200 copias/mL y 91 presentaron FV sin CVBG previa. De los 528 pacientes que tuvieron CVBG, 110 (20,1%) fallaron, riesgo 3,45 veces superior respecto a los que no tuvieron CVBG previa. El riesgo de FV fue 3,27 mayor para aquellos que tuvieron CVBG entre 51-200 copias/mL vs 20-50 copias/mL. Discusión: El estudio permite relacionar la CVBG con el FV posterior, siendo el mayor riesgo CVBG entre 51-200 copias/mL.


Abstract Background: Viral loads (VL) between 20-200 copies/mL are considered low-grade viral loads (LGVL). Its clinical implications and management have not been defined. Aim: To evaluate the impact of LGVL on the risk of subsequent development of virological failure (VF). Methods: Patients ≥ 18 years, with HIV-1 infection who had VL < 20 copies/mL for at least six months and/or in two consecutive samples under antiretroviral therapy (ART) were included, between January 1st, 2009 and December 31, 2019. Follow-up of the VLs was carried out stratifying them in VL < 20 copies/mL, LGVL (20-50 copies/mL and 51-200 copies/mL) and VF. Median follow-up 25 months (IQR 15-31). Results: 1,416 patients were included who reached VL < 20 copies/ml under ART, 797 patients remained with CV < 20 copies/mL during follow-up, 144 patients had VL between 21-50 copies/mL, 384 between 51-200 copies/mL and 91 had VF without previous LGVL. Out of 528 patients who had LGVL, 110 failed, risk 3.45 times higher than those who had no previous LGVL. Risk 3.27 times higher of VF for those who had LGVL between 51-200 copies/mL compared to 20-50 copies/mL. Discussion: The study allows to relate the LGVL with VF. This association was observed more frequently with LGVL between 51-200 copies/mL


Subject(s)
Humans , Viremia/etiology , HIV Infections/complications , HIV Infections/drug therapy , HIV-1 , Treatment Failure , Anti-HIV Agents/therapeutic use , Viral Load , Antiretroviral Therapy, Highly Active
4.
Rev. Assoc. Med. Bras. (1992) ; 66(3): 290-295, Mar. 2020. tab, graf
Article in English | LILACS, SES-SP | ID: biblio-1136208

ABSTRACT

SUMMARY The objective of this study was to verify the level of adherence to antiretroviral treatment and its associated factors. This is a descriptive cross-sectional study based on data retrieved from medical records. To achieve this, we used a questionnaire composed of sociodemographic and clinical information recorded from patients aged between thirteen and fifty-nine years who attended a specialized service from 2007 to 2014. The chi-square test was performed to verify the association of the outcome with the categorical variables. Continuous variables were compared through the Student t-test. Thirteen variables were analyzed in the bivariate model, resulting in the selection of the following variables to the multivariate model (p<0.20) age of discovery (p=0.12), age (p=0.14), skin color (p=0.12), level of education (p=0.03), time since HIV diagnosis (p<0.001) and AIDS case (p<0.001). Among the six variables selected for the multivariate model, cases of aids (p<0.001) remained significant. We concluded that having aids decreases the probability of non-adherence to antiretroviral treatment by 92%. These results indicate that symptomatic patients have better adherence to therapy.


RESUMO O objetivo deste estudo foi verificar os níveis de adesão ao tratamento antirretroviral e os fatores associados a ela. Trata-se de um estudo descritivo de delineamento transversal baseado em levantamento de prontuários. Para tanto, foi utilizado um questionário composto de informações sociodemográficas e clínicas de pacientes com idade entre 13 e 59 anos atendidos em um serviço de atendimento especializado nos anos de 2007 a 2014. Foi realizado o teste do Qui-quadrado para verificar a associação do desfecho com as variáveis categóricas. As variáveis contínuas foram comparadas pelo teste t de "Student" (dois grupos). Treze variáveis foram analisadas no modelo bivariado, sendo selecionadas para o modelo multivariado (p<0,20): idade de descoberta (p=0,12), idade (p=0,14), cor da pele (p=0,12), escolaridade (p=0,03), tempo de diagnóstico do HIV (p<0,001) e caso de aids (p<0,001). Das seis variáveis selecionadas para o modelo multivariado, permaneceu significante o fato de o paciente ter aids (p<0,001). Concluiu-se que ter aids reduz a probabilidade de não adesão ao tratamento antirretroviral em cerca de 92%. Os resultados indicam que o indivíduo que é sintomático adere melhor à terapia.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Young Adult , HIV Infections/drug therapy , Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active/statistics & numerical data , Medication Adherence/statistics & numerical data , Socioeconomic Factors , Brazil , Cross-Sectional Studies , Surveys and Questionnaires , Risk Factors , Patient Compliance , Medication Adherence/ethnology , Middle Aged
5.
Guatemala; Universidad del Valle de Guatemala. Programa Regional Centroamericano de VIH, MSPAS, CDC, PEPFAR, The University Norht Caroline; mar 2020. 99 p. ilus.
Monography in English | LILACS, LIGCSA | ID: biblio-1147330

ABSTRACT

In a qualitative study with both MSM and TW living with HIV in Guatemala City, Barrington et al (2016) again found that intersecting stigma and discrimination created fear of HIV testing and linkage to HIV care and barriers to knowledge about HIV. Retention-specific determinants included HIV clinic dynamics and limited employment opportunities, which affected economic stability. These multiple levels of factors driving linkage and retention in care and treatment require multi-level, integrated responses (AU)


Subject(s)
Humans , Male , Female , Adult , HIV Infections/diagnosis , HIV , Anti-HIV Agents/therapeutic use , Sexual Health , Social Support , Medical Informatics Applications , Prospective Studies , Fear/psychology , Social Stigma , Guatemala/epidemiology
6.
Rev. Soc. Bras. Med. Trop ; 53: e20200360, 2020. tab, graf
Article in English | LILACS, ColecionaSUS, SES-SP | ID: biblio-1143859

ABSTRACT

Abstract INTRODUCTION The first Brazilian HIV treatment recommendation was put forward in 1996, resulting in 12 subsequent guidelines. Several changes were made regarding "when" and "how" to begin treatment. The latest guideline recommends immediate initiation of antiretroviral therapy (ART). This study aimed to describe the evolution of HIV treatment among people living with HIV (PLHIV) who initiated ART between 2004 and 2018 based on the national guideline recommendations concerning T-CD4+ and VL measurements. METHODS A cross-sectional analysis of data of PLHIV aged >18 years, in Minas Gerais who received ART between 2004 and 2018 was conducted. Clinical, therapeutic, and demographic information were obtained from national healthcare databases. The study was divided into four periods: 2004-2007, 2008-2012, 2013-2016, and 2017-2018. Descriptive analyses were performed. RESULTS A total of 60,618 PLHIV initiated ART (67% male and 48% aged 25-39 years), 36% of whom had CD4 counts at ART initiation and 51% documented VL after ART initiation. The median CD4 count ranged from 288 to 373 cells/µL. The median time to ART initiation decreased from 604 to 28 days and was lower among males (p <0.01). The median time from ART initiation to the first VL result decreased from 101 to 62 days over the study period, while the median VL after ART initiation ranged from 2.3 to 1.7 log10 copies/ml. CONCLUSIONS Although our results demonstrated that most recommendations were followed, there seemed to be little impact on CD4 counts and VL testing. This may result in an inadequate evaluation of ART effectiveness.


Subject(s)
Humans , Male , Female , Adolescent , Adult , HIV Infections/drug therapy , Anti-HIV Agents/therapeutic use , Brazil/epidemiology , Cross-Sectional Studies , CD4 Lymphocyte Count , Viral Load
7.
Rev. Soc. Bras. Med. Trop ; 53: e20200333, 2020. tab, graf
Article in English | LILACS, ColecionaSUS, SES-SP | ID: biblio-1136832

ABSTRACT

Abstract INTRODUCTION: Achieving viral suppression (VS) in children is challenging despite the exponential increase in access to antiretroviral therapy (ART). We evaluated VS in children >1 year of age and adolescents 5 years after they had begun ART, in Manaus, Amazonas state, Brazil. METHODS: HIV-infected, ART-naive children >1 year of age between 1999 and 2016 were eligible. Analysis was stratified by age at ART initiation: 1-5 y, >5-10 y, and >10-19 y. CD4+ T-cell count and viral load were assessed on arrival at the clinic, on ART initiation, and at 6 months, 1 year, 2 years, and 5 years after ART initiation. The primary outcome was a viral load <50 copies/mL 5 years after ART initiation. RESULTS: Ultimately, 121 patients were included. The mean age at diagnosis was 4.8 years (SD 3.5), mean CD4% was 17.9 (SD 9.8), and mean viral load was 4.6 log10 copies/ml (SD 0.8). Five years after ART initiation, the overall VS rate was 46.9%. VS by patient age group was as follows: 36.6% for 1-5 y, 53.3% for >5-10 y, and 30% for >10-19 y. Almost all children (90,4%) showed an increase in CD4%+ T cell count. There were no statistically significant predictors for detecting children who do not achieve VS with treatment. VS remained below 65% in all the evaluated periods. CONCLUSIONS: Considerable immunological improvement is seen in children after ART initiation. Further efforts are needed to maintain adequate long-term VS levels and improve the survival of this vulnerable population.


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , HIV Infections/drug therapy , Brazil , HIV , CD4 Lymphocyte Count , Anti-HIV Agents/therapeutic use , Viral Load , Antiretroviral Therapy, Highly Active
8.
Rev. bras. epidemiol ; 23: e200020, 2020. tab
Article in Portuguese | LILACS | ID: biblio-1092600

ABSTRACT

RESUMO: Introdução: A vinculação é um passo fundamental para o cuidado contínuo da infecção pelo vírus da imunodeficiência humana (HIV/aids), sendo essencial para proporcionar o acesso à terapia antirretroviral, bem como ao cuidado integral. Metodologia: Estudo transversal, com pessoas vivendo com HIV (PVHIV), idade ≥ 18 anos, vinculadas entre janeiro e dezembro de 2015, em um serviço de referência para assistência ambulatorial e hospitalar especializada em HIV/aids em Belo Horizonte (MG). O tempo de vinculação foi definido como o tempo do diagnóstico até a vinculação ao serviço. Considerou-se vinculação oportuna quando esse tempo foi menor ou igual a 90 dias. Os dados foram coletados por meio de prontuários clínicos. Realizou-se análise de regressão logística com intervalo de confiança de 95% (IC95%). Resultados: Entre os 208 pacientes, a maioria era do sexo masculino (77,8%) com idade média de 39 anos. Cerca de 45% apresentaram condições definidoras de aids na vinculação. O tempo de vinculação apresentou média de 138 ± 397 dias, e a vinculação oportuna ocorreu para 76,9% dos pacientes. As variáveis associadas com a vinculação oportuna foram: ter idade ≥ 48 anos (odds ratio - OR = 8,50; IC95% 1,53 - 47,28), estar trabalhando (OR = 3,69; IC95% 1,33 - 10,25) no momento da vinculação e apresentar contagem de linfócitos T CD4 (LT CD4+) ≤ 200 células/mm3 no momento do diagnóstico de HIV (OR = 4,84; IC95% 1,54 - 15,18). Observou-se proporção importante de vinculação oportuna entre as PVHA, porém com diagnóstico tardio. Conclusão: Intervenções devem ser direcionadas para pessoas mais jovens e com maior contagem de LT CD4+, visando uma melhor prestação de cuidados contínuos em HIV.


ABSTRACT: Introduction: Linkage is a critical step in the ongoing care of human immunodeficiency virus (HIV/aids) infection and is essential for providing access to antiretroviral therapy, as well as comprehensive care. Methodology: Cross-sectional study on people living with HIV (PLHIV), aged ≥ 18 years old, linked between January and December 2015, in a referral service for outpatient and hospital care specialized in HIV/AIDS in Belo Horizonte, Minas Gerais. Linkage time was defined as the time from diagnosis to service linkage. Timely care linkage was considered when this time was ≤ 90 days. Data were collected through clinical records. A logistic regression analysis with a confidence interval of 95% (95%CI) was performed. Results: Among 208 patients, most of them were males (77.8%) with a mean age of 39 years. About 45% presented AIDS-defining conditions at the moment of linkage. Linkage time presented a mean of 138 ± 397 days. And timely linkage occurred for 76.9% of the patients. The variables associated with timely care linkage were: age ≥ 48 years (odds ratio - OR = 8.50; 95%CI 1.53 - 47.28), currently working (OR = 3.69; 95%CI 1.33 - 10.25) at the time of linkage, and present CD4+ T lymphocyte count (CD4+ T) ≤ 200 cells/mm3 at the time of HIV diagnosis (OR = 4.84; 95%CI 1.54 - 15.18). There was an important proportion of timely care linkage among PLHIV, but with late diagnosis. Conclusion: Interventions should be targeted at younger people with higher CD4+ T lymphocyte counts, in order to better provide continuous HIV care.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Young Adult , Referral and Consultation/statistics & numerical data , HIV Infections/drug therapy , Continuity of Patient Care/statistics & numerical data , Anti-HIV Agents/therapeutic use , Time-to-Treatment/statistics & numerical data , Health Services/statistics & numerical data , Health Services Accessibility/statistics & numerical data , Time Factors , Brazil/epidemiology , HIV Infections/diagnosis , HIV Infections/epidemiology , Cross-Sectional Studies , CD4 Lymphocyte Count , Antiretroviral Therapy, Highly Active , Delayed Diagnosis , Middle Aged
9.
Rev. latinoam. enferm. (Online) ; 28: e3228, 2020. tab, graf
Article in English | LILACS, BDENF | ID: biblio-1058545

ABSTRACT

Objective: to determine the contents that must be included in the usual counseling to improve the adherence to antiretroviral therapy (ART) of HIV patients, according to their different levels of alcohol consumption, and to determine the validity of the Counseling Guide in improving the adherence to ART in patients who consume alcohol using Implementation Science. Method: this is an observational study with formative and validation phases. The formative phase defined the content, approach and structure of the counseling. Validation included focus groups with patients and nurses, trial process by an expert and a pilot test. The criteria evaluated based on Implementation Science were: intervention source, evidence strength and quality, relative advantage, and complexity. The following criteria were also evaluated: usefulness, practicality, acceptability, sustainability, effectiveness; content consistency and congruence; procedural compliance and difficulties, and time spent in counseling. Results: the strength of evidence of the counseling is High-IIA, with strong level of recommendation and presenting usefulness, practicality, acceptability, sustainability and effectiveness. Eight in 11 experts argued that the Guide is clear, consistent and congruent. Initial counseling takes around 24 minutes; and follow-up counseling, 21. The instruments of the Guide present reliability levels between good and high (0.65 ≥ alpha ≤ 0.92). Conclusion: the Counseling Guide is valid to improve the adherence to antiretroviral therapy in patients who consume alcohol.


Objetivo: determinar os conteúdos que devem ser incluídos no aconselhamento habitual para melhorar a adesão ao TARV de pacientes com HIV, conforme seus diferentes níveis de consumo de álcool, e determinar a validade do Guia de Aconselhamento para melhorar a adesão ao TARV em pacientes que consomem álcool, usando a Ciência da Implementação. Método: estudo observacional com fase formativa e de validação. A fase formativa permitiu definir o conteúdo, a abordagem e a estrutura do aconselhamento. A validação incluiu grupos focais com pacientes e enfermeiras, processo de julgamento de especialista e teste piloto. Estes foram os critérios avaliados com base na Ciência da Implementação: fonte de intervenção, força e qualidade da evidência, vantagem relativa e complexidade. Foram avaliados ainda: utilidade, praticidade, aceitabilidade, sustentabilidade, efetividade; consistência e congruência do conteúdo; cumprimento, dificuldades do procedimento e tempo empregado no aconselhamento. Resultados: o aconselhamento tem força de evidência Alta -IIA, forte nível de recomendação, apresenta utilidade, praticidade, aceitabilidade, sustentabilidade e efetividade. Oito de 11 especialistas argumentaram que o Guia é claro, consistente e congruente. O aconselhamento de início leva em torno de 24 minutos; e o de acompanhamento, 21. Os instrumentos do Guia têm um nível de confiabilidade entre bom e alto (0,65 ≥ alfa ≤ 0,92). Conclusão: o guia de aconselhamento é válido para melhorar a adesão ao tratamento antirretroviral em pacientes que consomem álcool.


Objetivo: determinar los contenidos necesarios a incluir a la consejería habitual para mejorar la adherencia al TARV de pacientes con VIH según sus diferentes niveles de consumo de alcohol, y determinar la validez de la Guía de Consejería para mejorar la adherencia al TARV en paciente que consumen alcohol usando Ciencia de la Implementación. Método: estudio Observacional con fase formativa y de validación. La fase formativa permitió definir el contenido, enfoque y estructura de la consejería. La validación incluyó grupos focales con pacientes y enfermeras, juicio experto y prueba piloto. Los criterios evaluados en base a la Ciencia de la Implementación fueron: fuente de intervención, fuerza y calidad de la evidencia, ventaja relativa y complejidad. También se evaluó: utilidad, practicidad, aceptabilidad, sostenibilidad, efectividad; consistencia y congruencia del contenido; cumplimiento, dificultades del procedimiento y tiempo empleado en la consejería. Resultados: la consejería tiene fuerza de evidencia Alta -IIA, fuerte nivel de recomendación, presenta utilidad, practicidad, aceptabilidad, sostenibilidad y efectividad. Ocho de 11 expertos, sostuvieron que la Guía es clara, consistente y congruente. La consejería de inicio toma en promedio 24 minutos y 21 minutos la de seguimiento. Los instrumentos de la Guía tienen un nivel de fiabilidad entre bueno y alto (0,65 ≥ alfa ≤ 0,92). Conclusión: la guía de consejería es válida para mejorar la adherencia al tratamiento antirretroviral en pacientes que consumen alcohol.


Subject(s)
Humans , Male , Female , Alcohol Drinking , HIV Infections/drug therapy , Anti-HIV Agents/therapeutic use , Medication Adherence , Patient Education as Topic , Reproducibility of Results , Focus Groups , Counseling , Implementation Science , Nursing Care
10.
Rev. latinoam. enferm. (Online) ; 28: e3228, 2020. tab, graf
Article in English | LILACS, BDENF | ID: biblio-1094029

ABSTRACT

Objective: to determine the contents that must be included in the usual counseling to improve the adherence to antiretroviral therapy (ART) of HIV patients, according to their different levels of alcohol consumption, and to determine the validity of the Counseling Guide in improving the adherence to ART in patients who consume alcohol using Implementation Science. Method: this is an observational study with formative and validation phases. The formative phase defined the content, approach and structure of the counseling. Validation included focus groups with patients and nurses, trial process by an expert and a pilot test. The criteria evaluated based on Implementation Science were: intervention source, evidence strength and quality, relative advantage, and complexity. The following criteria were also evaluated: usefulness, practicality, acceptability, sustainability, effectiveness; content consistency and congruence; procedural compliance and difficulties, and time spent in counseling. Results: the strength of evidence of the counseling is High-IIA, with strong level of recommendation and presenting usefulness, practicality, acceptability, sustainability and effectiveness. Eight in 11 experts argued that the Guide is clear, consistent and congruent. Initial counseling takes around 24 minutes; and follow-up counseling, 21. The instruments of the Guide present reliability levels between good and high (0.65 ≥ alpha ≤ 0.92). Conclusion: the Counseling Guide is valid to improve the adherence to antiretroviral therapy in patients who consume alcohol.


Objetivo: determinar os conteúdos que devem ser incluídos no aconselhamento habitual para melhorar a adesão ao TARV de pacientes com HIV, conforme seus diferentes níveis de consumo de álcool, e determinar a validade do Guia de Aconselhamento para melhorar a adesão ao TARV em pacientes que consomem álcool, usando a Ciência da Implementação. Método: estudo observacional com fase formativa e de validação. A fase formativa permitiu definir o conteúdo, a abordagem e a estrutura do aconselhamento. A validação incluiu grupos focais com pacientes e enfermeiras, processo de julgamento de especialista e teste piloto. Estes foram os critérios avaliados com base na Ciência da Implementação: fonte de intervenção, força e qualidade da evidência, vantagem relativa e complexidade. Foram avaliados ainda: utilidade, praticidade, aceitabilidade, sustentabilidade, efetividade; consistência e congruência do conteúdo; cumprimento, dificuldades do procedimento e tempo empregado no aconselhamento. Resultados: o aconselhamento tem força de evidência Alta -IIA, forte nível de recomendação, apresenta utilidade, praticidade, aceitabilidade, sustentabilidade e efetividade. Oito de 11 especialistas argumentaram que o Guia é claro, consistente e congruente. O aconselhamento de início leva em torno de 24 minutos; e o de acompanhamento, 21. Os instrumentos do Guia têm um nível de confiabilidade entre bom e alto (0,65 ≥ alfa ≤ 0,92). Conclusão: o guia de aconselhamento é válido para melhorar a adesão ao tratamento antirretroviral em pacientes que consomem álcool.


Objetivo: determinar los contenidos necesarios a incluir a la consejería habitual para mejorar la adherencia al TARV de pacientes con VIH según sus diferentes niveles de consumo de alcohol, y determinar la validez de la Guía de Consejería para mejorar la adherencia al TARV en paciente que consumen alcohol usando Ciencia de la Implementación. Método: estudio Observacional con fase formativa y de validación. La fase formativa permitió definir el contenido, enfoque y estructura de la consejería. La validación incluyó grupos focales con pacientes y enfermeras, juicio experto y prueba piloto. Los criterios evaluados en base a la Ciencia de la Implementación fueron: fuente de intervención, fuerza y calidad de la evidencia, ventaja relativa y complejidad. También se evaluó: utilidad, practicidad, aceptabilidad, sostenibilidad, efectividad; consistencia y congruencia del contenido; cumplimiento, dificultades del procedimiento y tiempo empleado en la consejería. Resultados: la consejería tiene fuerza de evidencia Alta -IIA, fuerte nivel de recomendación, presenta utilidad, practicidad, aceptabilidad, sostenibilidad y efectividad. Ocho de 11 expertos, sostuvieron que la Guía es clara, consistente y congruente. La consejería de inicio toma en promedio 24 minutos y 21 minutos la de seguimiento. Los instrumentos de la Guía tienen un nivel de fiabilidad entre bueno y alto (0,65 ≥ alfa ≤ 0,92). Conclusión: la guía de consejería es válida para mejorar la adherencia al tratamiento antirretroviral en pacientes que consumen alcohol.


Subject(s)
Humans , Male , Female , Alcohol Drinking , HIV Infections , Reproducibility of Results , Focus Groups , Anti-HIV Agents/therapeutic use , Counseling , Medication Adherence , Implementation Science , Nursing Care
11.
Mem. Inst. Oswaldo Cruz ; 115: e200082, 2020. tab, graf
Article in English | LILACS, SES-SP | ID: biblio-1135226

ABSTRACT

Respiratory failure (RF) is the main cause of hospital admission in HIV/AIDS patients. This study assessed comorbidities and laboratory parameters in HIV/AIDS inpatients with RF (N = 58) in relation to those without RF (N = 36). Tuberculosis showed a huge relative risk and platelet counts were slightly higher in HIV/AIDS inpatients with RF. A flow cytometry assay for reactive oxygen species (ROS) showed lower levels in platelets of these patients in relation to the healthy subjects. However, when stimulated with adrenaline, ROS levels increased in platelets and platelet-derived microparticles of HIV/AIDS inpatients, which may increase the risk of RF during HIV and tuberculosis (HIV-TB) coinfection.


Subject(s)
Humans , Respiratory Insufficiency/complications , HIV Infections/blood , HIV/immunology , Reactive Oxygen Species/blood , Cell-Derived Microparticles/metabolism , Respiratory Insufficiency/blood , Blood Platelets , Biomarkers/blood , HIV Infections/complications , HIV Infections/drug therapy , Anti-HIV Agents/therapeutic use , Flow Cytometry
12.
Rev. saúde pública (Online) ; 54: 108, 2020. tab, graf
Article in English | LILACS, BBO, SES-SP | ID: biblio-1139469

ABSTRACT

ABSTRACT OBJECTIVE: To estimate the prevalence of smoking and evaluate the factors associated with this outcome in people living with HIV (PLHIV). METHODS: This is a cross-sectional study of a prospective concurrent cohort of 462 individuals initiating antiretroviral therapy at three HIV/AIDS specialized services in Belo Horizonte between 2015 and 2017. The following smoking status were used: current smoker (CS), former smoker (FS) and non-smoker (NS). Multinomial logistic regression was performed with NS as the reference category. RESULTS: Most participants were men (81.4%), young (up to 34 years old; 57.2%) and non-white (75.7%). Of the total number of individuals, 27.7% were CS, 22.9% FS, and 49.4% NS. Most smokers were light smokers (65.1%), consumed up to 10 cigarettes per day and had been smoking for more than 10 years (63.3%), starting on average at 17.2 years of age (SD = 5.1). In the multivariate analysis, higher chances of being CS were associated with: being female, having up to 9 years of schooling, current or prior use of alcohol and illicit drugs (marijuana, cocaine and crack) and presenting signs and/or symptoms of anxiety or depression. Higher chances of being FS were associated with having up to 9 years of schooling and current or prior use of alcohol and illicit drugs (marijuana and crack). CONCLUSIONS: The results show that smoking is highly prevalent among PLHIV, indicating the need for HIV specialized services to prioritize smoking cessation interventions. These interventions should consider the use of alcohol and illicit drugs and be targeted especially to young people, those with low schooling and with signs and/or symptoms of anxiety or depression.


RESUMEN OBJETIVO: Estimar a prevalência do tabagismo e avaliar os fatores a ele associados em pessoas vivendo com HIV (PVHIV). MÉTODOS: Trata-se de estudo transversal de uma coorte prospectiva concorrente com 462 indivíduos em início de terapia antirretroviral atendidos em três serviços de assistência especializada ao HIV/aids em Belo Horizonte entre 2015 e 2017. Os status de tabagismo utilizados foram: fumante atual (FA), ex-fumante (EF) e não fumante (NF). Realizou-se regressão logística multinomial, sendo NF a categoria de referência. RESULTADOS: A maioria dos participantes eram homens (81,4%), jovens (de até 34 anos; 57,2%) e não brancos (75,7%). Do total de indivíduos, 27,7% eram FA, 22,9% EF, e 49,4% NF. A maioria dos tabagistas eram fumantes leves (65,1%), consumiam até 10 cigarros por dia e fumavam havia mais de 10 anos (63,3%), tendo começado em média aos 17,2 anos de idade (DP = 5,1). Na análise multivariada, maiores chances de ser FA se associaram a: ser do sexo feminino, ter até 9 anos de escolaridade, usar ou já ter usado álcool e drogas ilícitas (maconha, cocaína e crack) e apresentar sinais e/ou sintomas de ansiedade ou depressão. Maiores chances de ser EF se associaram a ter até 9 anos de escolaridade e usar ou já ter usado álcool e drogas e ilícitas (maconha e crack). CONCLUSÕES: Os resultados mostram que o tabagismo é altamente prevalente entre PVHIV, indicando a necessidade de os serviços de assistência especializada em HIV priorizarem intervenções a fim de cessá-lo, com abordagem sobre o uso de álcool e drogas ilícitas, especialmente voltadas para pessoas jovens, com baixa escolaridade e com sinais e/ou sintomas de ansiedade ou depressão.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Smoking/epidemiology , HIV Infections/psychology , HIV Infections/drug therapy , Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active/methods , Socioeconomic Factors , Brazil/epidemiology , HIV Infections/epidemiology , Prevalence , Cross-Sectional Studies , Prospective Studies
13.
Einstein (Säo Paulo) ; 18: eAO4995, 2020. tab, graf
Article in English | LILACS | ID: biblio-1090037

ABSTRACT

ABSTRACT Objective To describe antiretroviral treatment regimens prescribed and their compliance with the Clinical Protocol and Therapy Guidelines of the Ministry of Health for the management of HIV infection. Methods Observational and descriptive study. Secondary data of the state of Paraná (Brazil) on drugs, treatment regimens, lines of treatment and number of individuals on treatment, from January to June 2018, were accessed at the Antiretroviral Agents Logistic Control System. Combinations of antiretroviral drugs (treatment regimens) were compared according to the current Clinical Protocol and Therapy Guidelines and non-compliances were classified and quantified. Results In Paraná, 35,127 individuals with HIV were treated with 253 different treatment regimens. Of the prescribed regimens, 19.1% were first-line, 27.4% second-line and 48.5% third-line. Among non-compliances, the most prevalent were absence of association of protease inhibitors and ritonavir (42.8%), low efficacy triple therapy (36.9%), double therapy (26.1%), monotherapy (20.3%), and triple therapy of nucleoside analog reverse transcriptase inhibitors (17.1%). Conclusion Most individuals receiving HIV treatment in the state of Paraná are on treatment regimens established in the current Clinical Protocol and Therapy Guidelines, which contributes to successful therapy. However, associations not provided by the current Clinical Protocol and Therapy Guidelines were identified in the initial treatment lines, which could lead to ineffectiveness, virologic failure and viral resistance.


RESUMO Objetivo Descrever esquemas terapêuticos de antirretrovirais prescritos e sua conformidade com o Protocolo Clínico e Diretrizes Terapêuticas, do Ministério da Saúde, para manejo da infecção pelo HIV. Métodos Estudo observacional e descritivo. Os dados do estado do Paraná sobre medicamentos que compõem os esquemas terapêuticos, linhas de tratamento e número de pessoas em uso destes foram acessados no Sistema de Controle Logístico de Medicamentos Antirretrovirais no período de janeiro a junho de 2018. As combinações de antirretrovirais (esquemas terapêuticos) foram comparadas conforme o Protocolo Clínico e Diretrizes Terapêuticas vigente, e as inconformidades foram categorizadas e quantificadas. Resultados No Paraná, 35.127 pessoas com HIV foram tratadas com 253 esquemas terapêuticos distintos. Dentre os esquemas prescritos, 19,1% eram de primeira linha, 27,4% de segunda linha e 48,5% de terceira linha. Nas inconformidades, predominaram a não associação entre inibidores da protease e ritonavir (42,8%), terapia tripla de baixa eficiência (36,9%), terapia dupla (26,1%), monoterapia (20,3%) e terapia tripla de inibidores da transcriptase reversa análogos de nucleosídeos (17,1%). Conclusão Maior parte das pessoas em tratamento do HIV no Paraná utilizam esquemas terapêuticos previstos no Protocolo Clínico e Diretrizes Terapêuticas vigente, o que contribui para o sucesso terapêutico. Entretanto, associações não previstas foram identificadas nas linhas de tratamento iniciais, podendo ocasionar inefetividade, falha virológica e resistência viral.


Subject(s)
Humans , Clinical Protocols/standards , Guideline Adherence/standards , Anti-Retroviral Agents/administration & dosage , Brazil , HIV Infections/drug therapy , Anti-HIV Agents/administration & dosage , Anti-HIV Agents/therapeutic use , Guideline Adherence/statistics & numerical data , Anti-Retroviral Agents/therapeutic use , Drug Therapy, Combination/standards , Drug Therapy, Combination/statistics & numerical data , Medication Adherence/statistics & numerical data
14.
Medwave ; 20(1): e7767, 2020.
Article in English | LILACS | ID: biblio-1087871

ABSTRACT

Elephantiasis nostras verrucosa, a rare manifestation of Kaposi's sarcoma, is a progressive cutaneous hypertrophy caused by chronic non-filarial lymphedema secondary to obstruction of the lymphatic system that can lead to severe disfigurement of parts of the body that have gravity-dependent blood flow, due to edema, fibrosis, and hyperkeratosis, especially lower extremities. Among the various conditions that can induce chronic lymphedema are tumors, trauma, radiotherapy, obesity, hypothyroidism, chronic venous stasis, and AIDS-related Kaposi's sarcoma. Kaposi's sarcoma is a vascular tumor associated with the presence of human gammaherpesvirus 8 that is predominantly cutaneous, locally aggressive, with metastasis, and is associated with the production of factors that favor inflammation, lymphatic obstruction, and lymphedema.


Subject(s)
Humans , Male , Middle Aged , Sarcoma, Kaposi/complications , AIDS-Related Opportunistic Infections/complications , Elephantiasis/diagnosis , Sarcoma, Kaposi/pathology , Sarcoma, Kaposi/drug therapy , Didanosine/therapeutic use , AIDS-Related Opportunistic Infections/pathology , AIDS-Related Opportunistic Infections/drug therapy , Lamivudine/therapeutic use , Anti-HIV Agents/therapeutic use , Cyclopropanes , Benzoxazines/therapeutic use , Drug Therapy, Combination , Elephantiasis/etiology , Elephantiasis/pathology , Alkynes
15.
Article in English | WPRIM | ID: wpr-878292

ABSTRACT

Objective@#To calculate the number of pregnant women who receive standardized prevention of mother-to-child transmission (PMTCT) services for HIV annually.@*Methods@#HIV-positive pregnant women in six counties of Liangshan Prefecture in 2017 were selected as study subjects. The entire process, from when the subjects first received the PMTCT of HIV services to the end, was divided into four stages, which were further divided into 25 phases. The equivalent coefficient was used to indicate the weight of workload in each phase. Seven experts were invited to score the equivalent coefficient; the number of pregnant women who received standardized services to prevent the transmission of HIV was calculated.@*Results@#A total of 663 HIV-positive pregnant women were registered in six Liangshan Prefecture counties in 2017. This figure was converted into 7,780 person-months devoted to HIV-positive pregnant women, with 260 person-months (3.34%) spent on the first antenatal care, 1,510 person-months (19.41%) during pregnancy, 378 person-months (4.86%) on delivery, and 5,632 person-months (72.39%) on post-partum period. The equivalent coefficient calculation showed that 314 HIV-positive pregnant women received standardized PMTCT services.@*Conclusion@#The number of pregnant women receiving standardized services for the PMTCT of HIV can be calculated accurately using the equivalent method to identify the gap between the level of PMTCT of HIV intervention services needed and the actual workload.


Subject(s)
Anti-HIV Agents/therapeutic use , Female , HIV Infections/virology , Humans , Infectious Disease Transmission, Vertical/prevention & control , Pregnancy , Pregnant Women
16.
Säo Paulo med. j ; 137(6): 479-485, Nov.-Dec. 2019. tab
Article in English | LILACS | ID: biblio-1094528

ABSTRACT

ABSTRACT BACKGROUND: Nonadherence to antiretroviral therapy (ART) may lead to viral replication and development of antiretroviral resistance. OBJECTIVE: To identify the factors associated with nonadherence to ART among people living with the human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) (PLWHA). DESIGN AND SETTING: Cross-sectional study in a tertiary-level hospital in northeastern Brazil. METHODS: Intake of less than 90% of the antiretroviral drugs prescribed in the last week prior to the interview was defined as nonadherence. Intake was evaluated using a questionnaire. Descriptive and multivariate analyses were conducted on the study population, with estimation of the respective odds ratios and 95% confidence intervals. RESULTS: The prevalence of nonadherence was 28.4%. Significant associations were found regarding the following variables: age less than 35 years, smoking, sedentary lifestyle, lack of medication and lack of knowledge regarding the patient's HIV status, on the part of the patient's partner or family. CONCLUSIONS: Encouragement of adherence to antiretroviral therapy is one of the fundamental pillars of treatment for HIV-infected patients. The high proportion of nonadherence (28.4%) and the predictive factors related to this indicate that it is necessary to improve patients' adherence to antiretroviral therapy.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Young Adult , HIV Infections/drug therapy , Anti-HIV Agents/therapeutic use , Antiretroviral Therapy, Highly Active/statistics & numerical data , Medication Adherence/statistics & numerical data , Treatment Adherence and Compliance/statistics & numerical data , Brazil/epidemiology , Attitude to Health , HIV Infections/epidemiology , Demography/statistics & numerical data , Prevalence , Cross-Sectional Studies , Surveys and Questionnaires , Antiretroviral Therapy, Highly Active/psychology , Medication Adherence/psychology , Treatment Adherence and Compliance/psychology
17.
Braz. j. infect. dis ; 23(6): 441-450, Nov.-Dec. 2019. tab, graf
Article in English | LILACS | ID: biblio-1089314

ABSTRACT

ABSTRACT Background: Antiretroviral therapy (ART) has decreased AIDS incidence and mortality, rendering comorbidities, such as hepatitis B more relevant for people living with human immunodeficiency virus (HIV). Since antiretroviral drugs may also inhibit hepatitis B virus (HBV) replication, analyzing the impact of ART on management of hepatitis B in this population is important. Objective: To assess HBV viremia among HIV/HBV coinfected individuals on ART and its associated factors. Method: For this cross-sectional study, HIV/HBV-coinfected individuals, aged over 18 years, who were on ART for over six months and receiving care at an outpatient clinic in São Paulo were recruited. Sociodemographic characteristics, information about viral exposure, clinical and laboratory data, including evaluation of liver fibrosis were obtained. Plasma HBV DNA was measured by polymerase chain reaction. Viral genome sequencing was conducted for genotyping and identification of drug resistance-conferring mutations if viral load exceeded 900 IU/mL. Results: Out of 2,946 patients who attended the clinic in 2015, 83 were eligible and 56 evaluated. Plasma HBV DNA was detected in 16 (28.6%) (95% CI: 18.0-41.3%), all on lamivudine and tenofovir treatment. HBV DNA detection was associated with lower education (p = 0.015), higher international normalized ratios (p = 0.045), history of an AIDS-defining illness [OR: 3.43 (95% CI: 1.10-11.50)], and HBeAg detection [OR: 6.60 (95% CI: 1.84-23.6)]. In contrast, a last CD4+ count above 500 cells/mm3 in the year prior to inclusion [OR: 0.18 (95% CI: 0.04-0.71)] and detection of anti-HBe [OR: 0.21 (95% CI: 0.04-0.99)] were negatively associated. Patients with HBV DNA above 900 IU/mL were infected with subgenotypes A1 (n = 3) and D2 (n = 1), and exhibited viral mutations associated with total resistance to lamivudine and partial resistance to entecavir. Conclusions: Despite being on ART, a significant proportion of HIV/HBV-coinfected individuals present HBV viremia. Characterization of factors that are associated with this finding may help professionals provide better management to these patients.


Subject(s)
Humans , Male , Female , Middle Aged , HIV Infections/virology , Anti-HIV Agents/therapeutic use , Viral Load/drug effects , Antiretroviral Therapy, Highly Active , Coinfection/virology , Hepatitis B/virology , Viremia , DNA, Viral/blood , HIV Infections/complications , HIV Infections/drug therapy , Hepatitis B virus/isolation & purification , Cross-Sectional Studies , Risk Factors , CD4 Lymphocyte Count , Educational Status , Hepatitis B/complications
18.
Rev. chil. infectol ; 36(4): 475-489, ago. 2019. tab
Article in Spanish | LILACS | ID: biblio-1042665

ABSTRACT

Resumen Introducción: La farmacocinética de los anti-retrovirales (ARVs) puede ser modificada por otros medicamentos de uso concomitante. Es oportuno actualizar las interacciones entre nuevos ARVs y fármacos de uso crónico para mantener un éxito terapéutico. Objetivo: Actualizar información sobre interacciones medicamentosas en pacientes con infección por VIH/SIDA en terapia antiretroviral. Método: Revisión estructurada en MEDLINE/ PubMed utilizando los términos Mesh: Anti-retroviral agents and drug interactions or herb-drug interactions or food-drug interactions, entre enero de 2015 y junio de 2017. Fueron seleccionadas publicaciones sobre interacciones medicamentosas en humanos, en inglés o español y con acceso a texto completo. Además, se incluyeron referencias de artículos considerados relevantes. La inclusión de los artículos fue evaluada por tres investigadores independientes y, en caso de requerirlo, por consenso entre ellos. La relevancia clínica se estableció, acorde con la gravedad y probabilidad de ocurrencia de la interacción. Resultados: Se identificaron 466 artículos, se accedió a texto completo a 444. De éstos, 164 aportaron interacciones, lo que permitió identificar un total de 534 parejas de interacciones medicamentosas. Las interacciones que presentaron un mayor riesgo de generar problemas de seguridad y efectividad fueron 308 (57,7%) de nivel 2 y 35 (6,6%) de nivel 1. Conclusiones: Se identifican 534 parejas nuevas de interacciones medicamentosas, de ellas 308 (64,2%) de mayor relevancia clínica.


Background: The pharmacokinetics of anti-retrovirals (ARVs) can be modified by other concomitant medicinal products. It is timely to update the interactions between new ARVs and drugs of chronic use to maintain therapeutic success. Aim: To update information about drug interactions in patients with HIV/AIDS on antiretroviral therapy. Methods: Comprehensive literature review in MEDLINE/PubMed database from January of 2015 to June of 2017, using the Mesh terms: Anti-retroviral agents and drug interactions or herb-drug interactions or food-drug interactions. Publications with drug interactions in humans, in English or Spanish, and with full text were retrieved. Additionally, citation lists from identified articles were reviewed. The study inclusion was assessed by three independent researchers and by consensus among them when was necessary. Clinical relevance of drug interaction was grouped into levels according to seriously and probability of occurrence. Results: 466 articles were identified; full text was accessed in 444. Of these, 164 provided interactions, which allowed the identification of a total of 534 pairs of drug interactions. The interactions that presented a higher risk of generating safety and effectiveness problems were 308 (57.7%) of level 2 and 35 (6.6%) of level 1. Conclusions: We identify 534 new pairs of drug interactions, of which 308 (64.2%) are the most clinically relevant.


Subject(s)
Humans , Protease Inhibitors/pharmacology , HIV Infections/drug therapy , Anti-HIV Agents/pharmacology , Drug Interactions , Protease Inhibitors/therapeutic use , Risk Factors , Anti-HIV Agents/therapeutic use
19.
Braz. j. infect. dis ; 23(3): 151-159, May-June 2019. tab
Article in English | LILACS | ID: biblio-1019551

ABSTRACT

ABSTRACT Background: HIV infection harms adaptive cellular immunity mechanisms. Long-term virological control by combined antiretroviral therapy (cART) reduces the risk of mycobacterial infections. Thus, we aimed to study cellular responses to mycobacterial antigens in 20 HIV-infected adolescents with at least one year of virological control (HIV-RNA <40 copies/mL) and 20 healthy adolescents. Methods: We evaluated CD8 and γδ T-cell degranulation by measurement of CD107a membrane expression after stimulation with lysates from BCG (10 µg/mL) and H37RA Mycobacterium tuberculosis (Mtb, 10 µg/mL). Immune activation and antigen-presenting ability were also assessed by determination of HLA-DR, CD80, and CD86 markers. Results: TCR γδ T-cell CD107a expression was similar between groups in response to mycobacterial antigens, and lower in the HIV-infected group in response to mitogen. Higher baseline HLA-DR expression and lower mycobacterial-stimulated expression was found within the HIV-infected group. Conclusions: Similar degranulation in stimulated CD8+ and TCR γδ T-cells from HIV-infected adolescents, when compared to healthy controls suggests long-term immunological preservation with immune reconstitution under successful cART. However, differences in HLA-DR expression may represent ongoing inflammation and lower specific responses in HIV-infected youth. These features may be relevant in the context of the precocity and severity of vertically acquired HIV infection.


Subject(s)
Humans , Male , Female , Young Adult , Receptors, Antigen, T-Cell, alpha-beta/immunology , AIDS-Related Opportunistic Infections/immunology , CD8-Positive T-Lymphocytes/immunology , Anti-HIV Agents/therapeutic use , Mycobacterium tuberculosis/immunology , Antigens, Bacterial/immunology , Tuberculosis/immunology , Biomarkers/blood , Cross-Sectional Studies , Prospective Studies , Immunophenotyping , Antigen Presentation/immunology , Infectious Disease Transmission, Vertical , Antigens, Bacterial/drug effects
20.
Rev. chil. infectol ; 36(1): 32-40, feb. 2019. tab, graf
Article in Spanish | LILACS | ID: biblio-1003654

ABSTRACT

Resumen Antecedentes: Los estudios clínicos orientados a evaluar la calidad de medicamentos genéricos pueden ser útiles para fortalecer políticas de acceso a terapia anti-retroviral combinada (TARc). Objetivo: Describir la efectividad y seguridad del esquema genérico lamivudina/tenofovir/efavirenz (3TC/TDF/EFV) en pacientes con infección por VIH/SIDA naïve, pertenecientes a un programa de atención integral. Materiales/Métodos: Estudio clínico prospectivo fase IV abierto y sin grupo control. Entre 2012-2014, se incluyeron y siguieron 40 pacientes con infección por VIH/SIDA naïve y con indicación para iniciar tratamiento. Los pacientes fueron tratados con el esquema genérico 3TC/TDF/EFV y fueron seguidos durante 12 meses. El seguimiento incluyó valoración clínica, parámetros inmunovirológicos y de laboratorio, al inicio del tratamiento y a los 3, 6 y 12 meses. Resultados: De los 40 pacientes, 30 (75%) cumplieron los doce meses de tratamiento; de ellos, 80% alcanzó CV indetectable (< 40 copias/mL) y 83,3% CV < 50 copias/mL. Adicionalmente, en el grupo hubo un incremento en la mediana de 173 linfocitos TCD4/mm3. Por su parte, los resultados del hemograma completo, creatininemia y transaminasas hepáticas se conservaron en rangos normales y no generaron cambios del TARc. Los efectos adversos reconocidos para estos medicamentos se presentaron en menos de 10% de los pacientes y no tuvieron implicaciones graves. Conclusiones: En este grupo pequeño de pacientes, el esquema genérico 3TC/TDF/EFV es efectivo y seguro en el tratamiento de pacientes con infección por VIH/SIDA naïve, y su perfil de efectividad y seguridad es similar al del esquema 3TC/TDF/EFV innovador en pacientes con condiciones clínicas similares.


Background: Clinical studies aimed to evaluating the quality of generic drugs may be useful to strengthen policies of access to combined antiretroviral therapy (cART). Aim: To describe the effectiveness and safety of the generic schema lamivudine/tenofovir/efavirenz (3TC/TDF/EFV) in patients with HIV/AIDS naive, belonging to a comprehensive care program. Methods: A nonrandomized, open-label, phase IV study, during 2012 to 2014 naive HIV-infected patients 18 years or older with indication to receive cART were recruited. Patients were treated with generic scheme 3TC/TDF/EFV and were followed-up during 12 months. Clinical, immunological and laboratory parameters were assessed at baseline, 3, 6 and 12 months of treatment. Results: Of the 40 patients, 30 (75%) met the 12 months of treatment; of them, 80% achieved undetectable viral load (< 40 copies/mL) and 83.3% viral load < 50 copies/mL. Additionally, there was a significant increase (173 cells/mm3) in the median for CD4 T lymphocyte count. Moreover, the results of the whole blood count, creatinine and transaminases were preserved in normal ranges and did not generate changes in the cART. Potential side effects of antiretroviral drugs occurred in less than 10% of patients and had no serious implications. Conclusions: In this small group of patients, the generic scheme 3TC/TDF/EFV is effective and safe in the treatment of patients with HIV/AIDS naïve, and its effectiveness and safety profile is similar to show by innovator scheme 3TC/TDF/EFV in patients with similar clinical conditions. Registro Estudio: Registro Público Cubano de Ensayos Clínicos (RPCEC) ID: RPCEC00000134. Registered 20 July 2012.


Subject(s)
Humans , Male , Female , Adult , Young Adult , Acquired Immunodeficiency Syndrome/drug therapy , Drugs, Generic/therapeutic use , Lamivudine/therapeutic use , Anti-HIV Agents/therapeutic use , Benzoxazines/therapeutic use , Tenofovir/therapeutic use , Time Factors , Prospective Studies , Reproducibility of Results , Analysis of Variance , Treatment Outcome , Colombia , Statistics, Nonparametric , Cyclopropanes , Alkynes
SELECTION OF CITATIONS
SEARCH DETAIL